
Chi-Yung Shang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/793786/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale – parent form. International Journal of Methods in Psychiatric Research, 2008, 17, 35-44.	2.1	262
2	Association between Morningness-Eveningness and Behavioral/Emotional Problems among Adolescents. Journal of Biological Rhythms, 2007, 22, 268-274.	2.6	234
3	Executive functions as endophenotypes in ADHD: evidence from the Cambridge Neuropsychological Test Battery (CANTAB). Journal of Child Psychology and Psychiatry and Allied Disciplines, 2010, 51, 838-849.	5.2	172
4	Psychiatric Comorbidity Among Children and Adolescents With and Without Persistent Attention-Deficit Hyperactivity Disorder. Australian and New Zealand Journal of Psychiatry, 2010, 44, 135-143.	2.3	129
5	Association between childhood sleep problems and perinatal factors, parental mental distress and behavioral problems. Journal of Sleep Research, 2006, 15, 63-73.	3.2	123
6	Associations Between Chronotypes, Psychopathology, and Personality Among Incoming College Students. Chronobiology International, 2012, 29, 491-501.	2.0	106
7	Association between symptoms and subtypes of attention-deficit hyperactivity disorder and sleep problems/disorders. Journal of Sleep Research, 2010, 19, 535-545.	3.2	103
8	Psychometric properties of the Chinese version of Strength and Difficulties Questionnaire. Comprehensive Psychiatry, 2013, 54, 720-730.	3.1	98
9	Psychometric Properties of the Chinese Version of the Swanson, Nolan, and Pelham, Version IV Scale-Teacher Form. Journal of Pediatric Psychology, 2009, 34, 850-861.	2.1	79
10	Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. International Journal of Neuropsychopharmacology, 2010, 13, 243.	2.1	78
11	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 447-460.	1.3	59
12	Increased gene expression of FOXP1 in patients with autism spectrum disorders. Molecular Autism, 2013, 4, 23.	4.9	53
13	A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1959-1973.	2.1	53
14	Whole Brain White Matter Tract Deviation and Idiosyncrasy From Normative Development in Autism and ADHD and Unaffected Siblings Link With Dimensions of Psychopathology and Cognition. American Journal of Psychiatry, 2021, 178, 730-743.	7.2	36
15	Executive Function in Adolescence Among Children With Attention-Deficit/Hyperactivity Disorder in Taiwan. Journal of Developmental and Behavioral Pediatrics, 2009, 30, 525-534.	1.1	35
16	The interactions between religion, religiosity, religious delusion/hallucination, and treatment-seeking behavior among schizophrenic patients in Taiwan. Psychiatry Research, 2011, 187, 347-353.	3.3	35
17	Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naÃ ⁻ ve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. European Neuropsychopharmacology, 2015, 25, 2300-2310.	0.7	33
18	Improving Visual Memory, Attention, and School Function with Atomoxetine in Boys with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 353-363.	1.3	30

CHI-YUNG SHANG

#	Article	IF	CITATIONS
19	Association between the dopamine transporter gene and the inattentive subtype of attention deficit hyperactivity disorder in Taiwan. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 421-428.	4.8	29
20	Emotional/Behavioral Problems and Functional Impairment in Clinic- and Community-Based Children with Attention-Deficit/Hyperactivity Disorder in Taiwan. Journal of Abnormal Child Psychology, 2010, 38, 521-532.	3.5	28
21	Impaired sustained attention, focused attention, and vigilance in youths with autistic disorder and Asperger's disorder. Research in Autism Spectrum Disorders, 2014, 8, 881-889.	1.5	26
22	An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 566-573.	1.3	26
23	Psychiatric Comorbidities in Adolescents with Attention- Deficit Hyperactivity Disorder and Their Siblings. Canadian Journal of Psychiatry, 2011, 56, 281-292.	1.9	23
24	Association between the DAT1 gene and spatial working memory in attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2014, 17, 9-21.	2.1	23
25	Differential brain activations in adult attention-deficit/ hyperactivity disorder subtypes: a counting Stroop functional MRI study. Brain Imaging and Behavior, 2018, 12, 882-890.	2.1	20
26	Demographic and perinatal factors for behavioral problems among children aged 4–9 in Taiwan. Psychiatry and Clinical Neurosciences, 2009, 63, 569-576.	1.8	19
27	Visual processing as a potential endophenotype in youths with attentionâ€deficit/hyperactivity disorder: A sibling study design using the counting Stroop functional MRI. Human Brain Mapping, 2018, 39, 3827-3835.	3.6	16
28	The norepinephrine transporter gene modulates intrinsic brain activity, visual memory, and visual attention in children with attention-deficit/hyperactivity disorder. Molecular Psychiatry, 2019, 26, 4026-4035.	7.9	15
29	Associations of symptoms and subtypes of attention-deficit hyperactivity disorder with visuospatial planning ability in youth. Research in Developmental Disabilities, 2013, 34, 2986-2995.	2.2	12
30	Maternal and Family Processes in Different Subgroups of Youth with Autism Spectrum Disorder. Journal of Abnormal Child Psychology, 2019, 47, 177-194.	3.5	11
31	Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 148-158.	1.3	11
32	Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 187-196.	1.3	11
33	A haplotype of the norepinephrine transporter gene (SLC6A2) is associated with visual memory in attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 58, 89-96.	4.8	8
34	Effects of the dopamine transporter gene on striatal functional connectivity in youths with attention-deficit/hyperactivity disorder. Psychological Medicine, 2021, 51, 835-845.	4.5	8
35	Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 9-19.	1.3	7
36	A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 164-178.	1.3	6

#	Article	IF	CITATIONS
37	Neural substrates underpinning intra-individual variability in children with ADHD: A voxel-based morphometry study. Journal of the Formosan Medical Association, 2022, 121, 546-556.	1.7	4
38	Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2783-2791.	2.2	3
39	Serotonin-Norepinephrine Reuptake Inhibitor–Associated Mixed Episode in an Adolescent With Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2014, 34, 525-526.	1.4	2